The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial

Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP

Published in JACC: Heart Failure

Methodology

Multicentre randomized, double-blind, placebo-controlled trial of coenzyme Q10 300 mg/day added to standard therapy in patients with moderate-to-severe chronic heart failure, followed for 2 years.

Key Findings

CoQ10 halved the rate of major adverse cardiovascular events (15% vs 26%) and reduced all-cause and cardiovascular mortality versus placebo, with improved NYHA class.

Conclusions

Long-term CoQ10 supplementation is safe and reduces major adverse cardiovascular events and mortality in chronic heart failure.

Limitations

Short-term functional endpoints at 16 weeks were not significantly different; moderate sample size for mortality outcomes; partly industry-supported.

Supplements Studied

CoQ10

Compound

CoQ10 halved the rate of major adverse cardiovascular events and reduced all-cause mortality versus placebo in chronic heart failure.

Outcomes Measured

Heart Health Support

CoQ10 halved the rate of major adverse cardiovascular events and reduced all-cause mortality versus placebo.

ATP Production Enhancement

Long-term coenzyme Q10 treatment reduced major adverse cardiovascular events in chronic heart failure.

CoQ10 Synthesis Support

CoQ10 halved the rate of major adverse cardiovascular events (15% vs 26%) and reduced all-cause and cardiovascular mortality versus placebo, with improved NYHA class.